U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug - Lilly Fires Warning Shot at Copycat Drug Makers After Shortage - Lilly slashes prices on lowest doses of weight loss drug Zepbound - Lilly's weight-loss drug cuts diabetes risk by 94% in three-year trial, company says - Lilly Gains in Obesity Race With Novo as Supplies Expand - FDA approves Eli Lilly Alzheimer's drug, expanding treatment options in the U.S. - FDA approves Lilly's new Alzheimer's drug after delay - Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks - FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval - China Urges Lilly to Boost Investing Amid US Cutoff Threat